MPS in the Pharmaceutical Industry: Opportunities, Successes & Barriers

MPS in the Pharmaceutical Industry: Opportunities, Successes & Barriers is organized by Select Biosciences and will be held on Nov 19, 2025 at voco Laguna Hills, Laguna Hills, California, United States of America.

Description:
This Summit held in tandem with the SelectBIO Lab-on-a-Chip and Microfluidics World Congress 2025 brings together the most up-to-date research efforts and technology developments in the Microphysiological Systems (MPS) space emphasizing the various organ-on-chip models that have been developed for studying both physiology and disease in in vitro model systems leveraging the tools and technologies of microfluidics.

Professor Kamm has assembled a collection of thought leaders from industry and academia to present the current state of the field and illustrate its applications across various functional areas. Topics will focus on the intersection of academia and the pharmaceutical industry and provide insights into the needs of pharma in disease modeling, drug development and toxicity screens that benefit from MPS technologies developed in university research and device comanies. It will also include a panel discussion on how to reach the full potential of MPS in the face of changing government priorities and the new FDA guidance.

This conference track -- in concert with the Lab-on-a-Chip and Microfluidics focus of this event -- describes an important and emerging application of microfluidics with strong emphasis by the pharmaceutical industry.

Agenda Topics, Themes Covered at this Summit:

• The unique challenges pharma faces in using MPS in their assay work stream including higher throughput, replicability and validation
• How can device manufacturers best meet the needs of pharma?
• How do various companies currently use MPS and for what applications?
• How much does cost influence the decision of pharma to adopt a new technology?
• How will the new FDA announcement “to phase out the animal testing requirement for monoclonal antibodies and other drugs” affect your use of MPS?
• Best practices in pharmaceutical applications
• Model qualification for assessing biologics and other delivery modalities
• Integrating PBPK computational methods with MPS
• What are the new questions of interest for pharma?
• What are some of the success stories of complex in vitro systems in your company?